---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-180313"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:05:54.017015+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Michael Davidson resigns from Silence Therapeutics board

## Summary
- Davidson resigned as director effective August 11, 2025, citing need to focus on other time commitments.
- He also stepped down from Audit, Risk, Remuneration, and Science & Technology Committees.
- Board reduced from five to four members; Iain Ross appointed to Audit and Risk Committee.
- Davidson remains CEO of NewAmsterdam Pharma; resignation not due to any disagreement with the Company.

## SEC filing metadata
- accession: 0001193125-25-180313
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525180313/0001193125-25-180313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525180313/d68551d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-180313
- JSON: https://secwatch.observer/filing/0001193125-25-180313.json
- Plain text: https://secwatch.observer/filing/0001193125-25-180313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.